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Abstract Fronto-striatal circuits constitute the neurobio-
logical basis of many neuropsychiatric disorders. Part of
the intracellular signaling within these circuits, including
its dopaminergic modulation, is regulated by the cyclic
adenosine monophosphate (cAMP)/protein kinase A (PKA)
signaling cascade. Based on the overall expression in
human fronto-striatal circuitry, we tested the effects of a
cAMP selective phosphodiesterase 4 (PDE4) inhibitor on
the tri-phasic response in the dorsomedial substantia nigra
pars reticulata (SNr) upon stimulation of the infralimbic
cortex in rats. Our results show for the first time that
stimulation of the cognitive infralimbic cortex leads to a
tri-phasic response in SNr neurons. In addition and in line
with previous biochemical and behavioral studies, PDE4
inhibition by roflumilast affects the direct pathway as well
as the indirect pathway of which the latter appears more
sensitive than the former.
Keywords Phosphodiesterase inhibitor  Roflumilast 
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Introduction
The fronto-striatal circuits are parallel organized circuits
running from the frontal cortex, through the basal ganglia
structures, to the thalamus from where they project back to
the frontal cortex (Alexander and Crutcher 1990; Alexan-
der et al. 1986). Therefore, the fronto-striatal circuits are
also known as cortico-striatal-thalamic circuits. The fronto-
striatal circuits can be divided into three groups based on
biological function, i.e., motor, associative/cognitive and
limbic (Alexander et al. 1986). All circuits are character-
ized by their modulation by dopamine at the level of the
striatum (Greengard 2001; Greengard et al. 1999; Sven-
ningsson et al. 2004) and their division into three pathways
within the basal ganglia, i.e., the hyperdirect pathway, the
direct pathway and the indirect pathway. Altogether, the
fronto-striatal circuits comprise a complex mechanism of
action and functionality, which is abundantly described
elsewhere (e.g., Calabresi et al. 2014; Gerfen and Surmeier
2011; Haber and Rauch 2010; Surmeier et al. 2011, 2007).
In short, the fronto-striatal circuits start with glutamatergic
projections into the striatum (caudate nucleus, putamen and
nucleus accumbens (NAc)). Within the basal ganglia all
projections are GABA (c-aminobutyric acid)-ergic except
for output from the subthalamic nucleus (STN) which is
glutamatergic. In the striatum each fronto-striatal circuit
splits into a direct and an indirect pathway. Cortical glu-
tamatergic activation of a striatal direct pathway stimulates
the release of GABA, having an inhibitory effect in the
globus pallidus pars interna (GPi) and substantia nigra pars
reticulata (SNr). As the GPi and SNr inhibit the thalamus,
which in turn stimulates the cortex, activation of the direct
pathway causes disinhibition of the thalamus leading to
increased excitatory output of the neural network, and
thereby activation of behavior (either motor, cognitive or
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limbic). The indirect pathway has the opposite effect.
Activation of the indirect pathway induces GABA release
in the globus pallidus pars externa (GPe) which normally
inhibits the release of GABA to the STN. The STN is thus
disinhibited and increases stimulation of the GPi/SNr,
which in turn inhibits the thalamic stimulation back to the
cortex and results in inhibition of behavior. Additionally,
the hyperdirect pathway consists of cortical glutamatergic
projections to the STN, thereby completely circumventing
the striatum. The disinhibition of the STN increases glu-
tamatergic excitation of the output nuclei (GPi/SNr).
Increased activation of the GPi/SNr results in increased
release of GABA from the GPi/SNr to the thalamus. This
increased inhibition of the thalamus results in inhibition of
the thalamic stimulation to the cortex. In the end, activation
of the hyperdirect pathways results in inhibition of
behavior. Without cortical stimulation the GPi and the SNr
function like autonomous pacemakers, tonically inhibiting
the thalamus, thereby preventing cortical stimulation, i.e.,
behavioral output.
In the striatum, dopaminergic neurotransmission is
regulated by the cyclic adenosine monophosphate (cAMP)/
protein kinase A (PKA) signaling cascade targeting effec-
tors like cAMP response element-binding protein (CREB)
and Dopamine- and cAMP-Regulated PhosphoProtein MR
32 kDa (DARPP-32) (Mayr and Montminy 2001; Sven-
ningsson et al. 2004). Consequently, dopaminergic signal-
ing is regulated by phosphodiesterases (PDEs), as cAMP is
degraded by PDEs. Because of its substrate cAMP and
based on the overall expression in human fronto-striatal
circuitry (Lakics et al. 2010), the PDE4 family is of par-
ticular interest (for a review see Heckman et al. 2016).
However, little is known regarding the distinct expression
of PDE4 within the three individual basal ganglia
pathways.
Therefore, in the current study we used an in vivo
electrophysiology approach to investigate the three basal
ganglia pathways. For this we measured extracellular
neural activity in the substantia nigra pars reticulata (SNr)
during frontal cortex stimulation (Kolomiets et al. 2003). In
particular, we were interested in the circuits involving
cognitive function rather than fronto-striatal circuits
involving motor or limbic functions (Deniau et al. 1996). In
rats, these encompass the fronto-striatal circuits originating
in the medial prefrontal cortex (mPFC; prelimbic and
infralimbic cortices) and the orbitofrontal cortex. We
focused on the circuit originating in the infralimbic cortex
instead of the prelimbic cortex or orbitofrontal cortex,
because sparse evidence confirms the existence of the three
pathways (hyper, direct and indirect pathways) in this
circuit. Also, the infralimbic cortex projections leave the
basal ganglia mainly via the ventral pallidum (e.g., Deniau
et al. 1994; Groenewegen et al. 1999) with less projections
via the SNr (Vertes 2004). We hypothesize that stimulation
of the infralimbic cortex may lead to a tri-phasic response
in the SNr (Maurice et al. 1999), topographically and
functionally associated with the ventral parts of the basal
ganglia. The temporal and topographic sensitivity of this
electrophysiological response combined could directly
address the distinctive effects, if any, of PDE4 inhibition in
the three basal ganglia pathways, and thus determine PDE4
function and PDE4 inhibitor applicability to specifically
influence fronto-striatal cognitive function.
Experimental procedures
Animals
A total of 24 male Wistar rats (age 3 months, 260–380 g,
Charles River, Margate, Kent, UK) were used. Animals
were housed collectively with ad libitum access to food and
water. In the animal facility a normal 12-h light/dark cycle
was maintained. In vivo electrophysiological experiments
including drug administration were conducted during day
time. All experiments were conducted at the University of
Oxford at the University Department of Pharmacology in
accordance with the Animals (Scientific Procedures) Act
1986 (UK) and were approved by a local Ethical Review
Process at the University of Oxford.
Electrophysiological recordings
General anesthesia was induced with isoflurane (Isoflu,
Abbott, Queenborough, Kent, UK) and maintained with
urethane (1.3–1.5 mg/kg, ethyl carbamate, Sigma, Stein-
heim, Germany), supplemented with doses of ketamine
(30 mg/kg, i.m.; Narketan, Vetoquinol, Buckingham,
Buckinghamshire, UK) and xylazine (10 mg/kg, i.m.;
Rompun, Bayer, Newbury, Berkshire, UK) whenever nec-
essary. Subsequently, animals were placed in a stereotaxic
frame (David Kopf Instruments, Tujunga, CA, USA).
Surgery site was pretreated with bupivacaine for local
anesthesia. Corneal dehydration was prevented by appli-
cations of Lacrilube eye gel (Allergan, Coolock, Dublin,
Ireland). Body temperature was maintained at 37 ± 0.5 C
using a homeothermic heating blanket (Harvard Apparatus,
Kent, UK).
An electrocorticogram (ECoG) was recorded over the
left motor cortex (2.6 mm posterior, 2.0 mm lateral to
bregma) to monitor the depth of anesthesia (see Schweimer
et al. 2011 for details). Craniotomies were performed
above the infralimbic cortex (3.2 mm anterior, 0.6 mm
lateral to bregma) for the stimulation electrode; and above
the SNr (5.2 mm posterior, 2.0 mm lateral to bregma) for
the recording electrode (Paxinos and Watson 2009). Saline
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was applied to the exposed brain surface to prevent
dehydration.
Extracellular neuronal activity was monitored with a
10–25 MX glass microelectrode filled with 1.5% Neuro-
biotin (Vectorlabs, Burlingame, CA, USA) in 0.5 M NaCl
(tip diameter 1–1.5 lm). The microelectrode was lowered
into the SNr with a single-axis in vivo micromanipulator
(IVM) controlled via LINLAB software (Scientifica, Uck-
field, UK). Electrode signals were alternating current (AC)-
coupled, amplified (1000x), and band-pass filtered
(0.3–5 kHz) using a Neurolog system (Digitimer, Welwyn
Garden City, Hertfordshire, UK) and acquired on-line
through a Micro1401 interface and Spike2 software
(Cambridge Electronic Design, Cambridge, Cam-
bridgeshire, UK). Mains noise at 50 Hz was eliminated
(‘Humbug’ filter, Brown et al. 2002) for single unit and
ECoG recordings.
Electrical stimulation of the medial prefrontal
cortex (infralimbic cortex)
Electrical stimulation of the infralimbic cortex (anterior:
3.2; lateral: 0.6 to bregma; ventral: -4.5 mm from the
cortical surface), ipsilateral to the recording SNr site, was
performed with a bipolar coaxial stainless steel electrode
(200 lm tip diameter, 500 lm shaft diameter, 500 lm
exposed inner and outer contact; NE-100 Harvard Appa-
ratus, UK) positioned stereotaxically according to Paxinos
and Watson (2009). Electrical stimuli were generated from
a constant current isolated stimulator (WPI A360 stimulus
isolator, Sarasota, Florida, USA) controlled via a Master-8
(A.M.P.I., Israel). Stimulation consisted of monopolar
pulses of 0.6 ms width and 500 lA intensity delivered at a
frequency of 1.4 Hz.
Drugs
All drugs were freshly prepared before each experiment.
Roflumilast (kindly provided by Takeda, Konstanz, Ger-
many) was administered i.v. in accumulating doses
(0.0025, 0.005 and 0.01 mg/kg). This was done to establish
a dose–response curve and maximizing the data per animal,
and thereby reduce animal numbers. Roflumilast was dis-
solved in 10% Kolliphor HS 15 (Sigma-Aldrich, Schnell-
dorf, Germany) and 90% isotonic saline (0.9%, Scheller
et al. 2014) to make it suitable for i.v. administration.
Extracellular single unit recordings of the SNr
neurons, pharmacological treatment
and experimental design
Initially, the recording electrode was lowered to: anterior:
-5.2 mm, lateral: 2.0 mm lateral to bregma; ventral:
-7.0 mm from the cortical surface according to Paxinos
and Watson (2009). For each experiment the dorsal border
of the SNr was located by identifying dopaminergic neu-
rons of the SNc. Criteria for dopaminergic SNc neurons
were broad action potentials ([ 1.1 ms), and low to mod-
erate frequency discharge (2–10 Hz) (Bunney et al. 1973;
Ungless and Grace 2012). Ventral of the SNc layer of
dopaminergic neurons, SNr neurons can be found. Elec-
trophysiological characteristics of the SNr neuron were
thin spikes (width\ 0.55 ms), high-frequency discharge
([ 10 Hz) without a decrease in the spike amplitude
(Bunney et al. 1973; Deniau et al. 1978; Kolomiets et al.
2003). Once an SNr neuron was detected a stable baseline
firing rate was established for 2 min, followed by a 2-min
stimulation period to check for the typical tri-phasic
response of the SNr (excitation–inhibition–excitation).
Presence of a tri-phasic response was also used as elec-
trophysiological characteristic of the SNr neuron. The
recording pattern was repeated if the neuron exhibited a tri-
phasic response to determine stable baseline spike train
parameters as well as a stable tri-phasic response; followed
by drug injections (i.v.) at 4-min intervals (2 min stimu-
lation off and 2 min stimulation on). This allowed for
testing of the effects of different doses of roflumilast on
baseline spike train parameters as well as the SNr tri-phasic
response (see Table 1).
Histochemistry
Following pharmacological treatment, animals were over-
dosed with pentobarbitone, brains were removed and kept
in 4% PFA overnight, before being transferred to a 30%
sucrose solution for cryoprotection. Coronal sections
(30 lm) were cut using a cryostat (Bright Instruments Ltd,
Luton, Bedfordshire, UK). Posterior sections containing
the complete SNr were checked using a light-microscope
(Leica Dialux 20) to verify recording electrode location.
Additionally, PFC sections were stained using a standard
Nissl-staining protocol to verify stimulation electrode
location. Prior to the Nissl-staining, sections were mounted
and hydrated in decreasing concentrations of ethanol.
Following the Nissl-staining, sections were first dehydrated
in increasing concentrations of ethanol and subsequently
treated with isopropanol and xylene. Sections were exam-
ined under a light-microscope (Leica Dialux 20). Bright-
ness and contrast of the images were adjusted using ImageJ
software (version 1.50, ImageJ, National Institute of
Health, Bethesda, MD, USA).
Data and statistical analysis
For the baseline periods, the interspike interval, coefficient
of variation of the interspike interval, firing rate, and spike
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waveform width (time taken from a 5% increase from
baseline to the first trough) were calculated for all neurons
(e.g., Brouard et al. 2015; Schweimer et al. 2011).
We calculated the peristimulus-time histograms (PSTH)
and response magnitudes as previously described in
Beyeler et al. (2010). PSTH were generated for every
2-min stimulation period (5-ms bins). The baseline was
defined as the mean of the spikes of the 100 ms epoch in
each, individual PSTH preceding the cortical stimulation.
In addition, the standard deviation (SD) of the baseline was
determined. A significant excitation was considered if the
mean of all bins within the excitatory epoch exceeded the
mean baseline activity by 2 SD. An inhibition was defined
as a period during which the mean of bins of the inhibitory
epoch is below 70% of the baseline mean (Georges and
Aston-Jones 2002).
Excitatory response magnitudes (Rmags) were normal-
ized for different levels of baseline activity, allowing for
comparison of drug effects on evoked responses indepen-
dent of effects on baseline activity or differences in firing
rate (Georges and Aston-Jones 2002). Rmags for excitation
were calculated with the following equation: Excitation
Rmag = (counts in excitatory epoch) - (mean counts per
baseline bin 9 number of bins in excitatory epoch). In
contrast, for the inhibition the Rmag is expressed in absolute
counts due to the low number of counts in the inhibition
period. Expressing these low counts in the same way as
positive Rmags induces artificially high values (i.e., per-
centages) and high variability. The count numbers during
the inhibition period were normally distributed and were
comparable between the neurons. Finally, to determine the
latency and the duration of each phase of the response,
PSTH were generated from ‘‘2 min of’’ trials using 1-ms
bins (Beyeler et al. 2010).
Statistical analysis was carried out using IBM SPSS
Statistics 24 software (IBM, Portsmouth, UK). The raw
data were checked for outliers and normality of distribu-
tion. Missing values were replaced using the multiple
imputation function in SPSS using 5 imputations (Olivier
et al. 2009). One-way repeated measures analysis of vari-
ance (ANOVA) followed by Sidak’s post hoc test was
used. Data are depicted as mean ± SEM.
Results
Effects of roflumilast on basal SNr neuron activity
To determine the effect of roflumilast in the cognitive
fronto-striatal circuit originating in the infralimbic cortex






0 Off Detection SNr neuron according to electrophysiological characteristics
2 Off Establishment of stable baseline firing
4 On Verification of typical tri-phasic response of the SNr (excitation–inhibition–excitation) after
stimulation infralimbic cortex
6 Off Verification stable baseline spike train parameters
8 On Verification stable tri-phasic response
10 Off Injection vehicle (i.v.)
10 Off Measuring effects dosing on baseline spike train parameters
12 On Measuring effects dosing on tri-phasic response
14 Off Injection 0.0025 mg/kg roflumilast (i.v.)
14 Off Measuring effects dosing on baseline spike train parameters
16 On Measuring effects dosing on tri-phasic response
18 Off Injection 0.005 mg/kg roflumilast (i.v.)
18 Off Measuring effects dosing on baseline spike train parameters
20 On Measuring effects dosing on tri-phasic response
22 Off Injection 0.01 mg/kg roflumilast (i.v.)
22 Off Measuring effects dosing on baseline spike train parameters
24 On Measuring effects dosing on tri-phasic response
26 Off Juxtacellular labeling or iontophoresis
86 Off Leave to settle
131 Off Transcardial perfusion
SNr substantia nigra pars reticulata, i.v. intravenous injection
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we recorded in 24 rats 65 neurons that exhibited an elec-
trophysiological profile corresponding to the SNr criteria
(see ‘Experimental procedures’ section). Figure 1 shows a
typical tri-phasic response of the SNr after infralimbic
cortex stimulation including baseline firing properties.
Recordings of these neurons showed that about 50% of
these neurons (n = 33) responded to electrical stimulation
of the infralimbic cortex (infralimbic cortex electrode
location verified; see Fig. 2). Among these 33 neurons only
18% showed a tri-phasic response (n = 6). This percentage
corroborates earlier findings observed in earlier studies
where the auditory-, motor-, and pre-limbic cortices were
stimulated (Kolomiets et al. 2003; Maurice et al. 1999).
Only SNr neurons exhibiting a tri-phasic response were
included in the analysis because they represent activation
of the full circuit of interest (see Fig. 2).
Before analyzing the effects of roflumilast on any of the
baseline spike train parameters or the tri-phasic response
we first verified that the (repeated) stimulation of the
infralimbic cortex or the injection had no effect on any of
the parameters investigated. Neither stimulation itself nor
the injection had an effect on the baseline firing (data not
shown). Subsequently, roflumilast had no effect on baseline
firing properties of the recorded neurons (firing rate, or
regularity (COV IS), data not shown).
The physiological response to stimulation of the SNr
neurons was compatible with previous data (Beyeler et al.
2010; Kolomiets et al. 2003; Ryan and Sanders 1994)
regarding the delay of appearance and the duration of each
phase of the tri-phasic response. Location of responding
(cognitive) neurons within the SNr is in line with the
division of motor, cognitive (associative) and limbic areas
within the SNr (e.g., Kolomiets et al. 2003).
Effects of roflumilast on mPFC stimulation-evoked
responses of SNr neurons
The tri-phasic response that was measured represents activa-
tion of the hyper direct, direct and indirect basal ganglia
pathways. Each individual pathway is measured as early
excitation, inhibition and late excitation, respectively. At
stimulation (no treatment), latencies and durations were as
follow (in ms ± SEM; n = 6) for the early excitation phase:
4.8 ± 1.4 and 10.8 ± 1.5, respectively. For the inhibition
phase this was 20.17 ± 1.8 and 12.67 ± 0.99, respectively,
and for the late excitation phase these values were 36.5 ± 2.5
and 13.67 ± 2.0, respectively. These valueswere not affected
during the different stages of the experiment and did not
change after roflumilast treatment. Thus, roflumilast had no
effect on the latency or duration of the tri-phasic response.
No effects of roflumilast were observed for the Rmag of
the early excitation phase (Fig. 3a). Roflumilast increased
the firing rate during the inhibition phase
(F (3,15) = 6.294, p = 0.006). Post hoc test revealed a
117% increase in the firing rate after 0.01 mg/kg (Fig. 3b;
p = 0.049). The calculated effect size for this difference
Fig. 1 Effects of roflumilast on




excitation) response of a SNr
neuron to infralimbic cortex
stimulation. Vertical line at
T = 0 represents the time of
stimulation; E1 = early
excitation phase of the tri-phasic
response; I = inhibition phase
of the tri-phasic response;
E2 = late excitation phase of
the tri-phasic response. Baseline
firing properties of SNr neurons
displaying a tri-phasic response
(N = 6): Average spike
waveform width:
0.0013 ± 0.00021 (s); Firing
rate (Hz): 25.89 ± 3.81;
Coefficient of variation of the
interspike interval:
0.25 ± 0.017; Latency first
excitation(s): 0.0048 ± 0.0014
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was 1.06 (Cohen’s D), which can be considered as a large
effect size. For the late excitation phase the Rmag the
repeated measures ANOVA showed a marginal treatment
effect (F (3,15) = 3.05, p = 0.06). However, post hoc
analysis revealed a 50% decrease in Rmag after 0.005 mg/
kg roflumilast treatment when compared with vehicle
(Fig. 3c; p = 0.035). The calculated effect size for this
difference was 1.58 (Cohen’s D), which can be considered
as a large effect size.
Discussion
The current study was conducted to address the potentially
distinctive effects of PDE4 inhibition on the three basal
ganglia pathways: the hyperdirect, direct and indirect
pathway. This was done by examining the effects on the
Fig. 2 Upper section: Graphical depiction of stimulation and
recording electrode locations for the 6 neurons exhibiting a tri-phasic
response (stimulation electrode: coronal section anterior: 3.2 mm to
bregma; recording electrode: coronal section anterior: -5.3 mm to
bregma). Lower section: On the left hand side, the medial prefrontal
cortex is shown including the large shaft created by the stimulation
electrode. The shaft extends from the dorsal surface of the brain
ventrally into the IL (Nissl-staining). On the right hand side, 2
figures are shown depicting the location of the tip of the recording
electrode in the SNr via iontophoresis (neurobiotin–streptavidin
staining). The lower image is a magnification of the upper image.
CG1 = cingulate cortex area 1; M2 = secondary motor cortex;
PL = prelimbic cortex; IL = infralimbic cortex; SNc = substantia
nigra pars compacta (dorsal tier); SNr = substantia nigra pars
reticulata; arrows indicate electrode tip locations















































































Fig. 3 Effects of the PDE4 inhibitor roflumilast on the magnitude of
the electrophysiological response of the SNr neurons to electrical
stimulation of the infralimbic cortex. Each bar represents the
magnitude of the response (Rmag as % of baseline for the early (E1)
and late (E2) excitation phases, and absolute counts for the inhibition
(I) phase). a Roflumilast did not affect the Rmag of the early excitation
phase. b Roflumilast decreased the magnitude of the inhibition as
depicted by an increase in the absolute number of counts at the
0.01 mg/kg dose. c In the late excitation phase a decrease in Rmag was
found at the 0.005 mg/kg dose
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tri-phasic (excitation–inhibition–excitation) response of the
SNr after infralimbic cortex stimulation. An increase or
decrease in the number of action potentials, as represented
by the Rmag or absolute numbers, within a particular phase
of the tri-phasic response, is indicative of an effect of
roflumilast in the pathway represented by that particular
phase of the tri-phasic response. Our results provide sup-
port for the hypothesis that PDE4 inhibition affects the
direct and indirect pathways of the basal ganglia, but not
the hyperdirect pathway. This conclusion is based on the
fact that roflumilast only affected the second and third
phases of the tri-phasic response, representing the direct
and indirect pathways, respectively. Roflumilast did not
change the Rmag in the first phase of the tri-phasic response,
representing the hyperdirect pathway. Therefore, we con-
clude that roflumilast does not exert effects in the hyper-
direct pathway. Since the hyperdirect pathway is also part
of the indirect pathway, the effects of roflumilast in the
indirect pathway observed during our studies, are most
likely not exerted in the trajectory of STN-SNr/GPi-thala-
mus. This conclusion is in line with previous findings
supporting a role for PDE4 in the direct and indirect
pathways originating in striatal medium spiny neurons
(Heckman et al. 2016; Nishi et al. 2008, 2011; Nishi and
Snyder 2010). The current data support the notion that
PDE4 has a preferential role in the indirect pathway since
PDE4 inhibition reduced the Rmag of the indirect pathway
at a lower dose when compared to the neuronal activity in
the direct pathway.
Previous studies showed that PDE4 predominantly regu-
lates cAMP/PKA signaling at striatal dopaminergic terminals
and associated dopamine synthesis and release (Nishi et al.
2008; Schoffelmeer et al. 1985; Yamashita et al. 1997a, b).
Secondary to this, PDE4 regulates cAMP/PKA signaling in
medium spiny neurons. This is the case for both the stri-
atopallidal as well as the striatonigral pathway as was
observed by increased levels of phospho-DARPP-32 in
neostriatal slices in both pathways after PDE4 inhibitor
treatment (Nishi et al. 2008). These findings were supported
by immunohistochemistry data. Of note, higher expression
levels were observed in (indirect) striatopallidal neurons but
only the PDE4B subtype was examined. Interestingly, PDE4
inhibition only potentiated adenosine A2a receptor –induced
phosphorylation of DARPP-32 by the adenosine A2a receptor
agonist CGS21680, whereas no additional effects of PDE4
inhibitionwere observed after stimulation of the dopamineD1
receptor with SKF81297 (Nishi and Snyder 2010). The latter
can be interpreted as a preferential effect of PDE4 inhibition in
striatopallidal neurons as A2a receptors are located on indirect
pathway medium spiny neurons and D1 receptors on direct
pathway medium spiny neurons (Gerfen and Surmeier 2011).
However, slices do not need to represent the in vivo
situation as for instance, as mentioned earlier, the observed
increase in DARPP-32 phosphorylation after rolipram
treatment in neostriatal slices could not be observed in vivo
by the same group (Nishi et al. 2008). Clearly, when
studying the fronto-striatal circuitry the striatal slices can
only model part of this circuitry and may therefore not be
the most suitable model for studying a fully intact func-
tional circuit. Therefore, the current study is unique in
providing support for a more sensitive indirect pathway for
PDE4 inhibition.
The more potent effect of roflumilast in the indirect
pathway can be hypothesized to occur from several pos-
sibilities. One option would entail lower levels of PDE4
expression in medium spiny neurons of the indirect stri-
atopallidal pathway compared to the direct striatonigral
pathway (Niccolini et al. 2017). This way, the same dose of
the compound can induce larger effects since absolute
lower number of PDE4 proteins in the indirect pathway
compared to the direct pathway. Another possibility to
explain the observed effect would be that the direct path-
way contains higher levels of PDE4 when compared to the
indirect pathway. That way a higher dose of roflumilast is
needed to inhibit higher levels of PDE4 compared to the
indirect pathway before cAMP and related signaling is
affected.
Also, the tri-phasic response measured in the SNr
originates in the frontal cortex and is modulated at many
different levels throughout the system before reaching the
output module of the basal ganglia. For instance, even
though the same intracellular effectors are involved in
frontal and striatal dopaminergic signaling, biosensor
imaging in mouse brain slice preparations showed pro-
found differences in the D1 response between pyramidal
cortical neurons and striatal medium spiny neurons (Castro
et al. 2013). Also, effects in other cognitive, motor or
limbic fronto-striatal circuits could affect the currently
investigated infralimbic circuit, including projections
coming from cingulate cortex, orbital cortex, parietal cor-
tex and temporal cortex (Schmitt et al. 2016). Furthermore,
it is unknown in which nigral and pallidal areas or where
within the subthalamic nucleus PDE4 is expressed (e.g.,
Niccolini et al. 2017). The abundant number of feedback
and feedforward connections within the circuits as well as
their mediation and modulation by several neurotransmitter
systems add to the complexity of predicting the net effect
reaching the output modules of the basal ganglia (Calabresi
et al. 2014; Gerfen and Surmeier 2011; Schmitt et al. 2016;
Surmeier et al. 2011). The latter aspects could be respon-
sible for the unexpected finding in both pathways, i.e.,
increased firing in the inhibition phase and decreased firing
in the late excitation phase after roflumilast treatment.
Future studies will have to investigate these possible
mechanisms at the cellular and molecular level further
(e.g., Nishi et al. 2017; Nishi and Shuto 2017).
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The functional implications of current results entail a
more promising role for PDE4 inhibitors, or at least rof-
lumilast, in disorders benefiting from less activation of the
indirect pathway, i.e., less inhibition to cortical areas. This
will add to the, in the current study neglected, main effect
of roflumilast at dopaminergic terminals, i.e., dopamine
release. Binding of dopamine to D1 and D2 receptors on
striatonigral and striatopallidal medium spiny neurons will
activate the direct pathway and inhibit the indirect path-
way, respectively. Together, this can be expected to greatly
benefit disorders characterized by hypodopaminergia,
including attention deficit hyperactivity disorder (ADHD)
and Parkinson’s disease.
Even though our results are in line with previous find-
ings in neostriatal slices and on behavioral outcomes, some
difference must be highlighted. For instance, in the current
study we examined the effects of a PDE4 inhibitor in
anesthetized animals while behavioral studies discussed
above examine fully awake and active animals. This means
that, although the brain circuitry is intact and functional, it
cannot be ruled out that different effects of roflumilast
could be observed when conducting electrophysiological
recordings in fully awake and freely moving animals. Since
PDE4 is most prominently expressed at dopaminergic ter-
minals affecting synthesis and release of dopamine in the
striatum, a dopaminergic challenge of the brain circuitry
may greatly affect fronto-striatal signaling. The latter is
more likely to occur in freely moving animals during
behavioral tasks compared to anesthetized animals (Sabeti
et al. 2003). However, the former would also introduce
more noise and thus variability in the data, when the
research question reflects merely the examination of the
effects of the drug. Another difference to address is that in
the study examining striatal slices, the classic PDE4 inhi-
bitor rolipram was used opposed to roflumilast in the cur-
rent study, even though both inhibitors are selective for
PDE4 over other PDE subfamilies and both have equal
selectivity for the four PDE4 subtypes (Hatzelmann et al.
2010; Krause and Kuhne 1988).
In line with previous studies (e.g., Deniau et al. 1994;
Groenewegen et al. 1999; Vertes 2004) cells exhibiting a tri-
phasic response were located in the dorsomedial SNr.
Results of the current study further add to the evidence that
cognitive projections, or at least those originating in the
infralimbic cortex, can induce a tri-phasic response in the
SNr. As a result, it also implies the existence of a division
within the basal ganglia into a hyper, direct and indirect
pathway, in the cognitive fronto-striatal circuit originating in
the infralimbic cortex. Thus, this also confirms the hypoth-
esis of the existence of the three pathways in the cognitive
fronto-striatal circuits as they do in the motor or limbic cir-
cuits (e.g., Beyeler et al. 2010; Maurice et al. 1999).
In conclusion, our results show that stimulation of the
infralimbic cortex leads to a tri-phasic response in a subset
of neurons in the SNr. This is topographically and func-
tionally associated with the cognitive parts of the basal
ganglia, that can be used to investigate distinctive effects of
drugs within the basal ganglia circuitry. The temporal and
topographic sensitivity of this tri-phasic electrophysiolog-
ical response combined with the neuroanatomical markers
directly addressed the distinctive effects of PDE4 inhibi-
tion by roflumilast in the three basal ganglia pathways of
the cognitive fronto-striatal circuitry. PDE4 inhibition by
roflumilast appears to affect both the direct pathway as well
as the indirect pathway with a relative preference for the
latter. These findings are in line with previous in vitro and
in vivo studies. Further studies may reveal whether PDE4
inhibition could be considered as a possible treatment for
cognitive deficits related to fronto-striatal disorders in
which either the direct or indirect pathway is affected (e.g.,
schizophrenia and ADHD, Huntington’s disease and
Parkinson’s disease).
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